Loxapine P-glycoprotein interactions in vitro

Drug Metabolism Letters

Volumn 6, Issue 1, 2012, Pages 26-32

  Reed, Andrea ^a   Huie, Keith ^a   Perloff, Elke S ^b   Cassella, James V ^a   Takahashi, Lori H ^a  

^a Alexza Pharmaceuticals   (United States)

^b BD Gentest Contract Research Services   (United States)

Author keywords

BCS; Caco 2; Digoxin; Inhibition; Loxapine; P glycoprotein; Permeability

Indexed keywords

DIGOXIN; KETOCONAZOLE; LOXAPINE; MANNITOL; MULTIDRUG RESISTANCE PROTEIN; PROPRANOLOL; GLYCOPROTEIN P; NEUROLEPTIC AGENT;

ARTICLE; CELL STRAIN CACO 2; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; DRUG USE; IC 50; IN VITRO STUDY; PRIORITY JOURNAL; STEADY STATE; DRUG ANTAGONISM; HUMAN; METABOLISM; TRANSPORT AT THE CELLULAR LEVEL;

ANTIPSYCHOTIC AGENTS; BIOLOGICAL TRANSPORT; CACO-2 CELLS; DIGOXIN; HUMANS; INHIBITORY CONCENTRATION 50; LOXAPINE; P-GLYCOPROTEIN;

EID: 84864955614     PISSN: 18723128     EISSN: None     Source Type: Journal    
DOI: 10.2174/187231212800229255     Document Type: Article

References (24)

1. Zhou, S-F. Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica, 2008, 38(7-8), 802-832.
2. Ayrton, A.; Morgan, P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica, 2001, 31(8/9), 469-497.
3. Moons, T.; de Roo, M.; Claes, S.; Dom, G. Relationship between P-glycoprotein and second-generation antipsychotics. Pharmacogenomics, 2011, 12(8), 1193-1211.
4. Rosenhagen, M.C.; Uhr, M. The clinical impact of ABCB1 polymorphism on the treatment of psychiatric diseases. Curr. Pharm. Des., 2011, 16, 2843-2851.
5. DePaulo, J.R. Jr.; Ayd, F.J. Jr. Loxapine: Fifteen years' clinical experience. Psychosomatics, 1982, 23(3), 261-271.
6. Boulton, D.W.; DeVane, C.L.; Liston, H.L.; Markowitz, J.S. In vitro P-glycoprotein affinity for atypical and conventional antipsychotics. Life Sci., 2002, 71, 163-169.
7. Wang, J-S.; Ruan, Y.; Taylor, R.M.; Donovan, J.L.; Markowitz, J.S.; DeVane, C.L. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int. J. Neuropsychopharmacol., 2004, 7(4), 415-9.
8. Wang, J-S.; Taylor, R.; Ruan, Y.; Donovan, J.L.; Markowitz, J.S.; DeVane, C.L. Olanzapine penetration into brain is greater in transgenic Abcb1a P-glycoprotein-deficient mice than FVB1 (wildtype) animals. Neuropsychopharmacol., 2004, 29, 551-557.
9. Kirschbaum, K.M.; Henken, S.; Hiemke, C.; Schmitt, U. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav. Brain Res., 2008, 188, 298-303.
10. Wang, J-S.; Zhu, H-J.; Donovan, J.L.; Yuan, H.J.; Markowitz, J.S.; Geesey, M.E.; DeVane, C.L. Aripiprazole Brain Concentration is Altered in P-glycoprotein Deficient Mice. Schizophr. Res., 2009, 110(1-3), 90-4.
11. Wang, J-S.; Zhu, H-J.; Markowitz, J.S.; Donovan, J.L.; DeVane, C.L. Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacol., 2006, 187(4), 415-423.
12. Zhu, H-J.; Wang, J-S.; Markowitz, J.S.; Donovan, J.L.; Gibson, B.B.; DeVane, C.L. Risperidone and paliperidone inhibit Pglycoprotein activity in vitro. Neuropsychopharmacol., 2007, 32, 757-764.
13. Palmeira, A.; Rodrigues, F.; Sousa, E.; Pinto, M.; Vasconcelos, M.H.; Fernandes, M.X. New uses for old drugs: pharmacophorebased screening for the discovery of P-glycoprotein inhibitors. Chem Biol. Drug Des., 2011, 78, 57-72.
14. U.S. FDA/CDER/CBER. Drug interaction studies-study design, data analysis and implications for dosing and labeling, Draft Guidance. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryI nformation/Guidances/UCM072101.pdf (Accessed December 2, 2011).
15. Elsby, R.; Surry, D.D.; Smith, V.N.; Gray, A.J. Validation and application of Caco-2 assays for the in vitro evaluation of development candidate drugs as substrates or inhibitors of Pglycoprotein to support regulatory submissions. Xenobiotica, 2008, 38(7-8), 1140-1164.
16. U.S. FDA/CDER. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryIn formation/Guidances/ucm070246.pdf (Accessed December 2, 2011).
17. Wu, C.Y.; Benet, L.Z. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmceutics drug disposition classification system. Pharm. Res., 2005, 22(1), 11-23.
18. Rautio, J.; Humphreys, J.E.; Webster, L.O.; Balakrishnan, A.; Keogh, J.P.; Kunta, J.R.; Serabjit-Singh, C.J.; Polli, J.W. In vitro Pglycoprotein inhibition assays for assessment of clinical drug interaction potential of new drug candidates: a recommendation for probe substrates. Drug Met. Disp., 2006, 34, 786-792.
19. Balimane, P.V.; Han, Y-H.; Chong, S. Current industrial practices of assessing permeability and P-glycoprotein interaction, AAPS J., 2006, 8, 1-13.
20. Anderle, P.; Niederer, E.; Rubas, W, Hilgendorf, C.L.; Spahn-Langguth, H.; Wunderli-Allenspach, H.; Merkle, H. P, Langguth, P. P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: the influence of culturing conditions and drug exposure on P-gp expression levels. J. Pharm. Sci., 1998, 87(6), 757-762.
21. Heel, R.C.; Brogden, R.N.; Carmine, A.; Morley, P.A.; Speight, T.M.; Avery, G.S. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections. Drugs, 1982, 23, 1-36.
22. Midha, K.K.; Hubbard, J.W.; McKay, G.; Hawes, E.M.; Hsia, D. The role of metabolites in a bioequivance study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int. J. Clin. Pharmacol. Ther. Toxicol., 1993, 31(4), 177-183.
23. Sokolski, K.N. Combination Loxapine and Aripiprazole for refractory hallucinations in schizophrenia. Ann. Pharmacother., 2011, 45, e36.
24. Wang, J-S.; Zhu, H-J.; Markowitz, J.S.; Donovan, J.L.; Yuan, H.J.; DeVane, C.L. Antipsychotic drugs inhibitor the function of breast cancer resistance protein. Basic Clin. Pharmacol. Toxicol., 2008, 103(4), 336-341.